About US
Contact us
-
Teva's trying to weasel out of its Mexican generics deal, new Rimsa lawsuit saysTurns out Teva didn’t quite know what it was getting itself into when it agreed to buy out Mexico’s Rimsa last year for $2.3 billion. The Israeli generics giant is suffering “buyer’s remorse” and loo2016/10/13
-
After Grassley decries 'incomplete response,' Mylan agrees to pony up EpiPen docsCongress is starting to get some answers on EpiPen pricing. And though, so far, Mylan’s not offering much beyond what’s readily available via Google search, that could change later this week. The Hou2016/10/12
-
Lundbeck pay-for-delay deals with Merck KGaA and others sized up by EU courtThe European Union's pushback on pay-for-delay arrangements among drugmakers is being tested today asits top court considers appeals from half a dozen drugmakers fined over deals with Denmark’s Lundbe2016/10/12
-
Think EpiPen is Mylan's first scandal? Here's a timeline of jet use, an unearned MBA and moreMylan’s ($MYL) EpiPentornadois far from its first storm of controversy. It’s just the most mainstream. Over the past decade, its executives have caught fire for personal use of company aircraft, an un2016/10/11
-
One, two, three, gone: Teva loses third patent on new Copaxone formulaThree strikes for the patentson Teva Pharmaceutical’s long-acting Copaxone formula: The U.S. Patent and Trademark Office’s review board has now invalidated the third of those patents to come up for re2016/10/11
-
Gilead faces another bid for hep C royalties as U of MN sues for patent infringementThe University of Minnesota wants a piece of Gilead Sciences’ megablockbuster hepatitis C business. The school sued Gilead for patent infringement Monday, claiming that the drugmaker’s sofosbuvir-bas2016/10/10
-
AstraZeneca settles lingering China bribery case with SECAstraZeneca has often been pointed to as a company that knows how to succeed in emerging markets like China, and CEO Pascal Soriot has made growth in these areas as one element of in his 5-part growth2016/10/10
-
Mylan faces more EpiPen scrutiny as House committee demands infoIf Mylan was hoping that its new EpiPen copay assistance and authorized generic would stave off government probing, then it’s hoping in vain. Another congressional commitee has piled on to Mylan and2016/10/9
-
AG lambasts Purdue for fighting his opioid marketing probePurdue Pharma’s highly addictive opioid Oxycontin has led to the company beingmaligned in lawsuits, by law enforcement officials and state and federal lawmakers. Now the Attorney General of New Hampsh2016/10/9
-
Insys sued by Illinois AG for off-label marketing of Subsys opioid sprayAfter a former Insys Therapeutics ($INSY) sales rep admitted she had paid kickbacks to doctors to prescribe the company's sprayed cancer pain opioid fentanyl for off-label uses, it was just a matter o2016/10/8